Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1141-1160 of 1,694 trials

ANCA-Associated Vasculitis: Prednisone Treatment Study

We are investigating whether continuing low-dose prednisone helps maintain remission in patients with ANCA-associated vasculitis compared to stopping it after one month. This study will also look at potential side effects and relapse rates over time.

Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis>2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesRheumatology

Solid Tumors: Long-Term Safety of Brigimadlin

We are studying the long-term effects of brigimadlin in people with solid tumors who have previously taken this medication. The goal is to understand how well they tolerate it and any side effects that may occur.

Solid TumoursEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

HER2+ Metastatic Colorectal Cancer: Tucatinib Combination Study

We are investigating whether a new treatment combining tucatinib, trastuzumab, and mFOLFOX6 can improve outcomes for patients with HER2+ metastatic colorectal cancer compared to standard care.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Dent 2 Disease: Alpelisib Study

We are testing the medication alpelisib in patients with Dent 2 disease to see if it improves kidney function and is safe to use. This study will help us understand its potential benefits for kidney health.

Dent's DiseaseEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNephrologyUrology

EBV Infection: Testing 2LEBV® and 2LXFS® for Fatigue

We are studying whether two new treatments can help reduce fatigue in patients with an EBV infection compared to a placebo. The trial also looks at other symptoms and safety.

Epstein-Barr Virus Infection>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesInfectious Diseases

Advanced Solid Tumors: Targeted Therapy Study

We are testing new targeted treatments for patients with advanced solid tumors to see how well they work for specific tumor types. This study aims to enhance personalized medicine in cancer treatment.

Malignant Solid Tumor>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Cholangiocarcinoma: Ivosidenib with Durvalumab and Gemcitabine/Cisplatin

We are studying a new treatment combination for patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The goal is to evaluate its safety and early effectiveness as a first-line therapy.

Cholangiocarcinoma>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Severe Functional Disorders: Duloxetine and Patient Education

We are studying the effects of patient education and duloxetine on individuals with severe functional disorders. This research aims to explore how these factors may influence symptoms and inflammation.

Functional Somatic Disorder3-6 monthsMonitoring phase (IV)Investigational MedicinesInternal MedicineNeurologyPsychiatry

Advanced NSCLC: NVL-655 Treatment Study

We are testing a new medication, NVL-655, for patients with advanced ALK-positive non-small cell lung cancer and other solid tumors. The study aims to evaluate its safety and effectiveness, especially for those with resistance to current treatments.

Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK MutationSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Mixed Dyslipidaemia: Rosuvastatin and Fenofibrate Study

We are comparing two medication combinations to see which one better lowers bad cholesterol in patients with mixed dyslipidaemia at high risk for heart disease. This study will help us understand their effectiveness and safety.

Dyslipidemia3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyEndocrinology

Primary Sclerosing Cholangitis: Norucholic Acid Tablets

We are studying the safety and tolerability of norucholic acid tablets for people with primary sclerosing cholangitis. We also want to see if it effectively helps manage their condition.

Primary Sclerosing Cholangitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyHepatology

Cystectomy: Targeted Antibiotic Prophylaxis Study

We are testing whether a personalized antibiotic treatment can help reduce hospital readmissions due to infections after bladder surgery. This study compares it to the standard antibiotic approach used during stent removal.

Bacterial Infection3-6 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesInfectious DiseasesUrology

Pseudomyxoma Peritonei: Neoadjuvant Chemotherapy Study

We are studying whether a combination of capecitabine and cyclophosphamide can help patients with large Pseudomyxoma peritonei before surgery. The goal is to see if this treatment improves tumor shrinkage and surgical success.

Pseudomyxoma Peritonei>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Ocular Melanoma: Roginolisib Treatment Study

We are studying the effectiveness of roginolisib for patients with advanced ocular or uveal melanoma compared to standard therapies. The trial will also assess safety and quality of life impacts.

Uveal MelanomaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOphthalmology

Idiopathic Retroperitoneal Fibrosis: Early Steroid Discontinuation Study

We are investigating whether stopping steroid treatment early in patients with idiopathic retroperitoneal fibrosis affects relapse rates. This study aims to improve treatment strategies for managing this condition.

Idiopathic Retroperitoneal Fibrosis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

Systemic Lupus Erythematosus: Cenerimod Study

We are examining the long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus. This study looks at how the medication works alongside existing treatments.

Systemic Lupus Erythematosus>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Breast Cancer: Patritumab Deruxtecan with Pembrolizumab

We are studying a new treatment combination for high-risk early-stage breast cancer patients to see if it improves tumor response compared to standard chemotherapy. This trial will help us understand the safety and effectiveness of this new approach.

Triple Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Short-Term Insomnia: Neurexan® Treatment

We are exploring whether Neurexan® can improve sleep quality and daytime performance in people with short-term insomnia. This study compares its effects to a placebo to understand its potential benefits.

Short-Term Insomnia>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteNeurologyPsychiatry

Kidney Transplant: Regulatory T Cell Therapy

We are studying the safety of using regulatory T cells in kidney transplant recipients to see if it helps the body accept the new kidney better. This may allow for less reliance on standard immunosuppressive medications.

Kidney TransplantationSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNephrology

Nivolumab and Entinostat for High-Risk Cancers in Kids

We are exploring a new treatment combining Nivolumab and Entinostat for children and adolescents with hard-to-treat cancers. The study aims to see if this combination can help those with specific tumor characteristics.

Relapsed or Refractory High-Risk Malignant Disease>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPediatrics